Sudarshan Chem. (SUDARSCHEM)

FairStock Score: 7/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Large revenue base: latest quarter sales of ₹2,103 Cr and reported sales growth of 215.56% show substantial operations and top-line momentum.
• Balance sheet leverage is moderate with Debt/Equity at 0.64, not a dangerously over-leveraged structure.
• Return on equity of 15.90% suggests the business has historically generated decent returns on book value.
• The stock is 43.8% below its 52-week high of ₹1,603.00, so some market de-rating has already occurred.

Concerns

• Extreme valuation: P/E of ~1,000 and PEG of 4.64 leave virtually no room for error; profit growth is -489%.
• Latest quarter net loss of ₹116 Cr on sales of ₹2,103 Cr indicates weak margins and negative profitability.
• ROCE of only 6.03% is below a satisfactory return on capital; capital allocation appears inefficient.
• Promoter holding is just 8.19%, raising serious governance and alignment concerns; Piotroski F-Score of 4/9 flags weak financial health.

AI Analysis

I begin with a simple question: what would I get for ₹901? A share of Sudarshan Chem promises ownership of a dye and pigment business with book value ₹154.56, yet I'm asked to pay 5.83 times that. With a P/E near 1,000 and reported profit growth of -489%, the market is capitalising almost no current earnings. The latest quarter is worse: sales of ₹2,103 Cr but a net loss of ₹116 Cr. That tells me the top line may be growing—215.56% reported—but margins or operations are destroying value. ROCE of only 6.03% is far below what I'd accept; I can get better returns without taking business risk. Debt/equity of 0.64 is manageable, and the reported ROE of 15.90% suggests the franchise can earn decent returns in good times, but the pigment industry is cyclical and today's numbers look like a downcycle with no margin of safety. Promoter holding of just 8.19% bothers me deeply; when owners have so little skin in the game, minority interests are not well aligned. The Piotroski F-Score of 4/9 and FairStock Score of 12/100 reinforce my caution. The stock has fallen from ₹1,603, but a falling knife is not a bargain. Valuation is still demanding, earnings are negative on a quarterly basis, and there is no evidence of a durable competitive advantage protecting margins. As Graham said, price is what you pay, value is what you get. Here, I cannot estimate value with any confidence. I would wait for proof of margin recovery and better owner alignment before considering an investment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer